Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 12/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MLYCD | O95822 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17276467 | 0.98 | HPGD (0.55) | HPGDALDH1A1PROKR1RIPK1MEN1 | |
| SCHEMBL21259942 | 0.96 | PROKR1 (0.47) | HPGDALDH1A1PROKR1RIPK1MEN1 | |
| SCHEMBL28471523 | 0.86 | RIPK1 (0.45) | HPGDALDH1A1PROKR1RIPK1MEN1 | |
| SCHEMBL13751474 | 0.84 | POLB (0.50) | HPGDRIPK1MEN1KMT2AKDM4E | |
| SCHEMBL1178863 | 0.84 | SMN1; SMN2 (0.53) | HPGDALDH1A1RIPK1KMT2AKDM4E | |
| SCHEMBL13741680 | 0.80 | HRH3 (0.50) | — | |
| SCHEMBL12698682 | 0.80 | CA12 (0.54) | HPGDALDH1A1PROKR1RIPK1MEN1 | |
| SCHEMBL5159792 | 0.78 | GAA (0.38) | ALDH1A1PROKR1MEN1KMT2AL3MBTL1 | |
| SCHEMBL22874860 | 0.78 | RIPK1 (0.48) | HPGDALDH1A1PROKR1RIPK1MEN1 | |
| SCHEMBL18689713 | 0.78 | SPR (0.51) | PROKR1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-10385057-B2 | Pyrazole compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385057-B2 | Pyrazole compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180327410-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2018-11-15 | — | — | US | disclosed |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-20100113776-A1 | PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO.,LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | HPGD 4099/4885ALDH1A1 2556/4885PROKR1 2316/4885 |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, FAAH, FAAH2 | HPGD 297/4885ALDH1A1 1322/4885PROKR1 2789/4885 |
| US-20180327410-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | FAAH, FAAH2, MGLL | HPGD 48/4885ALDH1A1 1378/4885PROKR1 3571/4885 |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABHD6, FAAH, FAAH2 | HPGD 297/4885ALDH1A1 1322/4885PROKR1 2789/4885 |
| US-20100113776-A1 | PYRAZOLE DERIVATIVE | HRH3, HRH4, HRH1 | HPGD 1756/4885ALDH1A1 2729/4885PROKR1 269/4885 |
| US-10385057-B2 | Pyrazole compounds and methods of making and using same | FAAH, FAAH2, MGLL | HPGD 48/4885ALDH1A1 1378/4885PROKR1 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.